Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
Journal of the National Comprehensive Cancer Network, 2017•jnccn.org
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because
therapeutic recommendations are rapidly changing for metastatic disease. For example,
new recommendations were added for atezolizumab, ceritinib, osimertinib, and
pembrolizumab for the 2017 updates.
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because
therapeutic recommendations are rapidly changing for metastatic disease. For example,
new recommendations were added for atezolizumab, ceritinib, osimertinib, and
pembrolizumab for the 2017 updates.
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
jnccn.org
以上显示的是最相近的搜索结果。 查看全部搜索结果